Zimmer Biomet reported a 9.3% increase in first quarter net sales to $2.087 billion and a 15.5% rise in adjusted diluted earnings per share to $2.09. The company generated $245.9 million in free cash flow and completed $250 million in share repurchases. Key product launches and clinical milestones support growth, prompting Zimmer Biomet to raise its adjusted EPS guidance for 2026. The company remains confident in its strategy for sustained long-term growth.
Zimmer Biomet has appointed Chintan Desai as president of its Asia Pacific region, effective immediately. Desai brings nearly 30 years of leadership experience in the medical technology sector, including senior roles at Alcon and GE Healthcare. He re...
Zimmer Biomet Holdings announced its second quarter 2026 earnings conference call will be held on August 5 at 8:30 a.m. ET, with a news release detailing results available earlier that day. The call will be webcast live and available for replay on th...
